NASDAQ:AGIO

Agios Pharmaceuticals Stock News

etoro logo Buy AGIO
*Your capital is at risk
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
Nuveen Asset Management LLC lifted its stake in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 45.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Com
Agios has strong cash balance and is trading near 52-week lows. In these times of pandemic, its solid pipeline offers a good investment opportunity. Since this
Man Group plc decreased its holdings in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 75.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC
Agios Pharmaceuticals (NASDAQ:AGIO) and Evoke Pharma (NASDAQ:EVOK) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their prof
Geode Capital Management LLC boosted its holdings in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 16.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm
Bank of New York Mellon Corp boosted its position in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 9.7% during the fourth quarter, according to the company in its most recent filing with the Securities &
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB), Alnylam Pharma (ALNY) and Agios Pharma
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Bank of America Corp DE grew its holdings in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 77.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (S
ARCH Venture Partners today announced the closing of two new funds, ARCH Venture Fund X and ARCH Venture Fund X Overage, with a combined $1.46 billion to invest in transformative, early stage biotechn
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the European Medicines Agency (EMA) Committee for Orpha
BidaskClub upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a sell rating to a hold rating in a research note published on Thursday, BidAskClub reports. Several other research analysts have
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE